Hematologic TestsNCT00768547
Risk Stratification in Acutely Admitted Medical Patients
An observational study of Hematologic Tests, run by Ribe County Hospital at 1 site in Denmark.
Trial summary
The study has three main parts. 1. To see if we can develop a riskstratification tool that can be used to asses the risk for acutely admitted medical patients for inhospital death, admission to the ICU and death within 30 days of release. 2. To test existing tool as in 1. 3. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Hematologic Tests
- How many people
- 5,900 participants
- Where
- 1 siteDenmark
- Study dates
- Aug 2008to Jul 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Any patient acutely admitted to the medical department of Ribe County Hospital
Who may be able to join
- Any patient acutely admitted to the medical department of Ribe County Hospital
Who cannot join
- Age below 15 years
- Unwilling to participate
Trial locations and contacts
1 site in 1 country.
About this study
The study has three main parts.
- To see if we can develop a riskstratification tool that can be used to asses the risk for acutely admitted medical patients for inhospital death, admission to the ICU and death within 30 days of release.
- To test existing tool as in 1.
- To clarify if it is most reasonable to let the admitting doctor order blood test by clinical judgment or be using a predefined list of tests.
- Conditions
- Hematologic Tests
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| By protocol | Where the test are predefined | |
| By degression | The group where the doctor decided which test are to be taken. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of test taken in each group
Measured: Five months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2008 (estimated)
- Study startAug 2008
- Primary completionJul 2011
- Study completionJul 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematologic TestsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5,900 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ribe County Hospital
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00768547
- Sponsor's protocol ID
- risk stratification
- Status last verified
- Aug 2008
- First submitted
- 7 Oct 2008
- Last updated
- 22 Jul 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Stratification in Acutely Admitted Medical Patients
- ClinicalTrials.gov ID
- NCT00768547
- Acronym / sponsor ID
- risk stratification
- Conditions
- Hematologic Tests
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 5,900 participants (actual)
- Lead sponsor
- Ribe County HospitalUniversity, hospital or other
- Study start
- Aug 2008
- Primary completion
- Jul 2011 (actual)
- Study completion
- Jul 2011 (actual)
- First posted
- 8 Oct 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study has three main parts.
- To see if we can develop a riskstratification tool that can be used to asses the risk for acutely admitted medical patients for inhospital death, admission to the ICU and death within 30 days of release.
- To test existing tool as in 1.
- To clarify if it is most reasonable to let the admitting doctor order blood test by clinical judgment or be using a predefined list of tests.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| By protocol | – | –Where the test are predefined |
| By degression | – | –The group where the doctor decided which test are to be taken. |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Any patient acutely admitted to the medical department of Ribe County Hospital
Key inclusion criteria (1 listed)
- Any patient acutely admitted to the medical department of Ribe County Hospital
Key exclusion criteria (2 listed)
- Age below 15 years
- Unwilling to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of test taken in each group
Time frame: Five months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2011.
Related trials for Hematologic Tests
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Recruiting
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
B-All, Acute Lymphoblastic Leukemia
Active, not recruitingPhase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 4
Hematological Safety of Dipyrone Versus Paracetamol After Dental Extractions
Hematologic Test, Agranulocytosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hematologic Tests, run by Ribe County Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of test taken in each group (time frame: Five months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2011.